• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Thursday, November 19, 2026
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Biology

Computational Screen Prioritizes Early-Stage MMP-13 Inhibitor Candidate

by
November 9, 2026
in Biology
Reading Time: 7 mins read
0
Computational Screen Prioritizes Early-Stage MMP-13 Inhibitor Candidate

Computational Screen Prioritizes Early-Stage MMP-13 Inhibitor Candidate

Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Researchers published a computational study in BMC Biotechnology identifying P4C-BM as an early-stage candidate for inhibiting matrix metalloproteinase-13, an enzyme implicated in cartilage degeneration associated with knee injuries. The study, led by Aijuan Zhang and colleagues, utilized an integrated in silico workflow to screen and prioritize small-molecule inhibitors without performing experimental validation. The findings are strictly computational, serving as a hypothesis-generating step for future biological testing rather than a demonstration of therapeutic efficacy or clinical benefit.

Post-traumatic osteoarthritis is a progressive joint disease that develops after structural or mechanical damage to the knee, such as anterior cruciate ligament rupture or meniscal tears. These injuries alter joint loading and trigger inflammatory responses that shift cartilage metabolism toward degradation. Matrix metalloproteinase-13, also known as collagenase-3, plays a central role in this process by cleaving type II collagen, the primary structural component of articular cartilage. Because mature cartilage has limited regenerative capacity, enzymatic breakdown of the collagen network leads to long-term structural consequences.

The study aimed to identify potential small-molecule inhibitors of human MMP-13 using a multi-step computational approach. The workflow included retrieving the canonical MMP-13 sequence from the UniProt database, characterizing its physicochemical properties, and predicting its secondary and tertiary structures. The team used the experimentally resolved crystal structure PDB ID: 1XUC as the structural reference for pharmacophore generation and binding-site interpretation, ensuring that the computational models were grounded in known biological data.

Physicochemical profiling of the 471-amino-acid MMP-13 protein was conducted using the EXPASy ProtParam tool to assess target tractability. Secondary structure predictions were generated using SOPMA and PSIPRED, with PSIPRED predicting 13.4% alpha-helix, 11.5% beta-sheet, and 75.1% coil. Tertiary structure modeling involved AlphaFold and GalaxyRefine, with the refined model achieving an ERRAT overall quality factor of 91.6667%. These structural characterizations provided the foundation for subsequent ligand screening and docking analyses.

Pharmacophore-based screening was performed using the Pharmit web server to identify candidate ligands from the PubChem database. The screened set included Mmp13-IN-3 and various P4DC and P4C-series compounds. ADMET and toxicity predictions were carried out using TOXCSM, while drug-likeness was assessed using Lipinski rule-of-five criteria. Among the evaluated compounds, 14 of 21 P4DC series derivatives passed the full battery of toxicity analysis, but only 9 met both TOXCSM and Lipinski criteria. P4C-BM was accepted by the ADMET screen but did not fully satisfy Lipinski rule-of-five criteria due to its molecular weight of 594.62 g/mol and topological polar surface area of 184.68 Ų.

Molecular docking analysis using CB-Dock2 revealed predicted binding energies ranging from −7.2 to −9.4 kcal/mol. P4DC-FMePh-TzTri showed the most favorable predicted docking score of −9.4 kcal/mol, followed by P4C-BM at −8.9 kcal/mol. Despite not having the highest docking score, P4C-BM was prioritized as the lead candidate based on a combined profile that included its predicted ADMET acceptance, interaction pattern, and molecular dynamics stability. The docking scores are interpreted as preliminary computational ranking values rather than experimentally validated binding affinities.

Protein-ligand interaction analysis of the MMP-13–P4C-BM complex identified conventional hydrogen bonds involving residues HIS24 and GLN195, along with hydrophobic contacts involving PRO166, GLY169, GLY194, LEU20, ALA2, and LEU136. These interactions provide a structural rationale for the predicted docking pose, suggesting that P4C-BM can occupy the predicted binding region. However, interaction mapping alone does not demonstrate enzymatic inhibition or selectivity against other MMP family members such as MMP-1, MMP-2, MMP-8, or MMP-9.

A single 100 ns molecular dynamics simulation was performed to assess the stability of the MMP-13–P4C-BM complex. The protein backbone RMSD stabilized at approximately 2.0 Å, and the ligand RMSD fluctuated within less than 3.0 Å, indicating that the ligand remained in the binding site without major displacement. MM-GBSA calculations estimated the binding free energy at approximately −44.7 kcal/mol, suggesting strong thermodynamic affinity. However, because only one trajectory was simulated, the results do not establish statistical reproducibility, and replicate simulations are required to confirm the observed stability.

Protein-protein interaction and gene co-expression analyses using the STRING database provided biological context for MMP-13. The network included cartilage-associated proteins such as TIMP1, TIMP2, ADAMTS4, ADAMTS5, ACAN, and COL10A1. These associations support the biological relevance of MMP-13 in extracellular matrix remodeling and cartilage degeneration pathways. However, these network analyses were not used to rank compounds or validate inhibitor activity; they served only to contextualize the target selection.

The study has significant limitations, primarily that all findings are based on computational prediction and have not been experimentally validated. No biochemical inhibition assays, selectivity testing, chondrocyte experiments, cartilage explant models, or in vivo animal studies were performed. The ADMET and toxicity findings are predictive and require experimental pharmacokinetic and toxicological confirmation. Therefore, P4C-BM should be regarded only as a candidate for further experimental validation in enzymatic assays, chondrocyte models, and in vivo osteoarthritis models.

Current treatment strategies for knee injury-related cartilage degeneration, including non-steroidal anti-inflammatory drugs, corticosteroids, and platelet-rich plasma, have variable structural outcomes and uncertain long-term disease-modifying effects. Broad-spectrum MMP inhibitors have shown limited clinical translation due to poor target selectivity and dose-limiting adverse effects, such as musculoskeletal syndrome. Selective MMP-13 inhibition is considered a rational strategy to reduce type II collagen cleavage while minimizing off-target toxicity, but it remains an experimental approach requiring rigorous preclinical validation.

The prioritization of P4C-BM highlights the utility of integrated in silico workflows in reducing the number of compounds requiring synthesis and biological testing. By combining pharmacophore screening, docking, ADMET prediction, and molecular dynamics simulation, the study provides a structured framework for early-stage drug discovery. However, the transition from computational lead to clinical candidate depends on successful experimental validation of direct MMP-13 inhibition and cartilage-protective effects in biological systems.

The biological rationale for targeting MMP-13 stems from its specific role in the degradation of the articular cartilage matrix. Articular cartilage is primarily composed of type II collagen, aggrecan, and proteoglycan-rich extracellular matrix, which provide tensile strength and compressive resistance within the knee joint. Because mature articular cartilage is avascular and aneural, it possesses limited intrinsic regenerative capacity. Consequently, once the type II collagen framework is disrupted by enzymatic activity, the tissue becomes susceptible to progressive degeneration, and repair becomes difficult. In the context of post-traumatic osteoarthritis, mechanical stress and inflammatory mediators such as interleukin-1β and tumor necrosis factor-α can increase the expression and activity of matrix-degrading enzymes. This shifts the balance between extracellular matrix synthesis and degradation toward breakdown, making selective inhibition of MMP-13 a potential strategy to slow this process.

Previous attempts to develop broad-spectrum matrix metalloproteinase inhibitors have faced significant clinical challenges. These non-selective agents often result in musculoskeletal syndrome, a condition characterized by arthralgia, myalgia, joint stiffness, tendon pain, and reduced mobility. These adverse effects are thought to arise from the inhibition of multiple MMP family members involved in normal connective tissue remodeling, rather than the selective inhibition of a single disease-relevant enzyme. Therefore, the development of selective MMP-13 inhibitors is considered a more rational approach, aiming to reduce cartilage matrix degradation while minimizing off-target musculoskeletal toxicity. However, the development of such selective inhibitors remains challenging because MMP family members share conserved catalytic domains and overlapping binding-site features, which increases the risk of poor selectivity.

The computational workflow in this study was designed to address these challenges by integrating multiple analysis steps. The team utilized the experimentally resolved MMP-13 crystal structure, PDB ID: 1XUC, as the structural reference for pharmacophore generation and binding-site interpretation. This approach ensured that the computational models were grounded in known biological data rather than relying solely on predicted structures. The pharmacophore model included hydrophobic, aromatic, hydrogen-bond donor, and hydrogen-bond acceptor features derived from the ligand-binding region. Candidate ligands were retrieved from the PubChem database and screened against this model. The identified compounds, including Mmp13-IN-3 and various P4DC and P4C-series derivatives, were retained for subsequent analysis based on their match to the pharmacophore features, although pharmacophore matching alone does not demonstrate inhibitory activity.

The ADMET and toxicity screening revealed significant bottlenecks in the candidate compounds. Among the P4DC series derivatives, 14 of 21 compounds passed the full battery of toxicity analysis using TOXCSM. However, only 9 of these compounds met both the TOXCSM criteria and the Lipinski rule-of-five criteria for drug-likeness. P4C-BM was accepted by the ADMET screen but did not fully satisfy the Lipinski rule-of-five criteria. Its molecular weight of 594.62 g/mol and topological polar surface area of 184.68 Ų indicate that it falls outside some classical oral drug-likeness ranges. These predicted pharmacokinetic descriptors suggest potential limitations in passive permeability and oral bioavailability, indicating that pharmacokinetic optimization or local delivery strategies may be required before biological testing.

The molecular dynamics simulation provided insights into the stability of the predicted complex. The protein backbone RMSD stabilized at approximately 2.0 Å, and the ligand RMSD fluctuated within less than 3.0 Å, suggesting that the ligand remained in the binding site without major displacement. The MM-GBSA calculated binding free energy averaged at approximately −44.7 kcal/mol in the last simulation frames, suggesting strong thermodynamic affinity. However, the study explicitly notes that only a single 100 ns trajectory was performed. Therefore, these results do not establish statistical reproducibility of the complex stability. Independent replicate simulations using different initial velocity seeds are required to confirm whether the observed RMSD, RMSF, and hydrogen-bond persistence patterns are reproducible. The docking protocol was also not validated through redocking of a co-crystallized ligand, which limits confidence in the predicted binding pose accuracy.

Clinical and translational evidence supports the relevance of MMP-13 in osteoarthritis and knee injury-associated joint degeneration. Studies have reported associations between circulating MMP-13 levels and radiographic severity in patients with primary knee osteoarthritis. Additionally, meniscal MMP-13 expression has been associated with increased preoperative pain in patients undergoing arthroscopic partial meniscectomy for meniscal tears. These findings suggest that MMP-13-targeted strategies may be relevant not only for cartilage degeneration but also for symptomatic meniscal injury. However, these associations remain translational hypotheses that require experimental and clinical validation. The current study does not provide patient-level data, clinical outcomes, or biomarker validation, and its findings should be interpreted strictly as hypothesis-generating computational evidence.

Subject of Research: In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis

Article Title: In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis

Article References: Zhang, A., Chen, H., Song, N., Zhuang, J., Chen, B., Lin, X., Jin, S., & Chen, C. (2026). In silico prioritization of potential matrix metalloproteinase-13 inhibitors for cartilage degeneration in knee injury-associated osteoarthritis. BMC Biotechnology, 26(1), Article 121. https://doi.org/10.1186/s12896-026-01200-7

Image Credits: AI Generated

DOI: 10.1186/s12896-026-01200-7

Keywords: silico, prioritization, potential, matrix, metalloproteinase-13, inhibitors, cartilage, degeneration, knee, injury-associated, osteoarthritis, scientific research

News Source: Gregory Coleman. (November 9, 2026). Computational Screen Prioritizes Early-Stage MMP-13 Inhibitor Candidate. Scienmag.

Tags: cartilagedegenerationinhibitorsinjury-associatedkneeMATRIXmetalloproteinase-13osteoarthritispotentialprioritizationscientific researchsilico
Share12Tweet7Share2ShareShareShare1

Related Posts

Low HLA-A Expression and NK Cells Linked to Pediatric HIV Remission

Low HLA-A Expression and NK Cells Linked to Pediatric HIV Remission

November 19, 2026
Decades-Long Field Survey Unveils Plant Diversity Powering China's Traditional Zongzi Culture

Decades-Long Field Survey Unveils Plant Diversity Powering China’s Traditional Zongzi Culture

November 19, 2026

Engineered Escherichia coli Yields Eight Grams Per Liter of Fatty Alcohols

November 19, 2026

Targeting GPCR-Gαq Signaling Overcomes Trametinib Resistance in BRAF-Mutant Melanoma

November 19, 2026

POPULAR NEWS

  • Somatic Symptom Burden in Oral Health Clinic Patients Shifted Modestly Across Pandemic

    Somatic Symptom Burden in Oral Health Clinic Patients Shifted Modestly Across Pandemic

    29 shares
    Share 12 Tweet 7
  • Multicenter ICU Study Identifies Nurse Knowledge Gaps in Pneumonia Prevention

    29 shares
    Share 12 Tweet 7
  • Study Finds One-Third of Ethiopian Neuropsychiatric Patients Exhibit Harmful Alcohol Use

    29 shares
    Share 12 Tweet 7
  • Low-Dose Epidural Analgesia Modestly Lengthens Labor Stages in Low-Risk Women

    29 shares
    Share 12 Tweet 7

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Study Links Specific Dietary Patterns to Atherosclerotic Cardiovascular Disease in Upper Egypt

PCR Testing Shows Malaria Prevalence Rose in Remote Peruvian Amazon Communities

Low HLA-A Expression and NK Cells Linked to Pediatric HIV Remission

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 89 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.